Please login to the form below
Balversa
This page shows the latest Balversa news and features for those working in and with pharma, biotech and healthcare.
Cancer Research Horizons and Newcastle University extend alliance with Astex
Astex subsequently entered into a drug discovery collaboration and licence agreement on FGFR inhibitors with Janssen – a pharmaceutical arm of Johnson &Johnson – which resulted in the identification of Balversa (erdafitinib), approved
Latest news
-
J&J taps TARIS Biomedical for novel bladder cancer technology
J&J has a strong presence in the bladder cancer area, with its targeted bladder cancer drug Balversa (erdafitinib) gaining approval in the US earlier this year. ... With Balversa, a 99-patient study demonstrated a 40% overall response rate, 3% complete
-
Incyte claims FDA priority review for bile duct cancer drug
Other FGFR inhibitors being tested for bile duct cancer include Johnson &Johnson’s Balversa (erdafitinib) – approved earlier this year for FGFR-mutated bladder cancer – as well as Bridge Bio’s infigratinib.
-
J&J’s targeted bladder cancer treatment gets US approval
Balversa is first FGFR inhibitor. Johnson &Johnson’s highly anticipated bladder cancer drug Balversa has been approved in the US, becoming the first personalised treatment targeting a certain type of genetic ... We recognise the significant unmet need
More from news
Approximately 2 fully matching, plus 2 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- World Health Organization releases latest set of COVID-19 guidelines
- BeiGene’s Brukinsa receives FDA approval for chronic lymphocytic leukaemia
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Eli Lilly announces $450m investment in US manufacturing site
- Europe’s cancer community publishes new report on transforming patient care
- EU outlines measures to mitigate antibiotic shortage across Europe
- Innovative Trials comments on extra funding to increase access to clinical trials for cancer patients
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- JCVI recommends autumn COVID-19 vaccine booster for those at highest risk
- MIT researchers develop AI model to detect future lung cancer risk
- Merging global and local pharmacovigilance operations into a successful integrated approach
- Diversifying Healthcare AI with Federated Learning
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- World Health Organization releases latest set of COVID-19 guidelines
- AbbVie and Eli Lilly leave UK’s voluntary drug pricing agreement
- EU to revise pharmaceuticals law amid antibiotic shortages
- European MPs call for urgent action against antimicrobial resistance
- The role of medical communications in building credibility for healthtech
PMHub
Branding Science
We are Branding Science Partners in thinking which inspires change in healthcare Branding Science are an award-winning global pharmaceutical market...
Latest intelligence
- Virtual Steering Committee & Peer Influence Program
- In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program....
- Meeting healthcare’s rising challenges
- The journey to discover novel therapies through digital innovation and ensure scientific advances achieve their potential...
- Report gives insights to address gaps in HCP engagement
- How does Pharma-HCP engagement need to evolve in today's digital landscape?...
